Drug-induced hypothyroidism


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Hypothyroidism is characterized by thyroid hormones deficit endocrinopathy, which could initiated by different reasons. Last years the raise of incidence of drug-induced hypothyroidism was noted. Hypothyroidism considered drug-associated if patient takes drug which known as reason of decrease thyroid function or hypothyroidism resolves by this drug withdrawal. Risk factors of drug-induced hypothyroidism are already established hypothyroidism, concomitant autoimmune disease, previously established thyroiditis Hashimoto, thyroidectomy, effect Wolff-Chaikoff realization (blockade of thyroid hormone synthesis when a large amount of iodine is introduced into the organism; living in districts with sufficient iodine intake, family history (the presence of disease in relatives), eating disorders. The most frequent reason of drug-induced hypothyroidism is amiodarone intake, tetracycline antibiotics, tyrosine kinase inhibitor, anticancer drugs, anti-epileptic drugs, as well as iodine-containing contrast agents. For the treatment of drug-induced hypothyroidism, it is necessary to cancel the drug, against the background of which it has developed, in addition, resort to replacement therapy with levothyroxine sodium. As a preventive measure for drug-induced hypothyroidism, it is recommended to avoid using drugs with this side effect and use an adequate amount of iodine to prevent iodine deficiency, and correct thyroid dysfunction in a timely manner.

全文:

受限制的访问

作者简介

Olga Ostroumova

Russian Medical Academy of Continuous Professional Education

Email: ostroumova.olga@mail.ru
Dr. Sci. (Med.), Professor Moscow, Russia

V. Kachan

Samara State Medical University

Samara, Russia

A. Kochetkov

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

G. Krasnov

N.I. Pirogov Russian National Research Medical University; Russian Clinical and Research Center of Gerontology

Moscow, Russia

参考

  1. Rizzo L.F.L., Mana D.L., Serra H.A. Drug-induced hypothyroidism. Med. (B Aires). 2017;77(5):394-404.
  2. Taylor P.N, Albrecht D., Scholz A., et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-16. Doi: 10.1038/ nrendo.2018.
  3. Tisdale J.E., Miller D.A. Drug-induced diseases: prevention, detection, and management. 2nd ed. Bethesda, Md.: American Society of Health-System Pharmacists, 2010.
  4. George J., Joshi S.R. Drugs and Thyroid. J Assoc Phys India. 2007;55:215-12.
  5. Maynard S., Miller R.G. Drug-Induced Hypothyroidism. Labmed. 2017 [cited 2019 Jul 19]. URL: https://www.clinicaladvisor.com/ home/decision-support-in-medicine/labmed/ drug-induced-hypothyroidism.
  6. Tisdale J.E., Miller D.A. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists, 2018.
  7. Mir S.A., Wani A.I., Masoodi S.R., et al. Lithium toxicity and myxedema crisis in an elderly patient. Indian J Endocrinol Metab. 2013;17(Suppl.:S654-56. doi: 10.4103/22308210.123558.
  8. Luster M., Duntas L.H., Wartofsky L., ed. The Thyroid and Its Diseases. A Comprehensive Guide for the Clinician. Springer International Publishing, 2019.
  9. Miyake Z., Ishii K., Tamaoka A. Hypothyroidism induced by phenytoin and gabapentin: Case Rep. Med. (Baltimore). 2018;97(43):e12938. doi: 10.1097/MD.0000000000012938.
  10. Вернигородский В.С., Власенко М.В., Паламарчук А.В. и др. Терапевтические маски гипотиреоза. Міжнародний ендокринологический журнал. 2018;14(5):503-7.
  11. Pigatto P.D., Guzzi G. Aloe Linked to Thyroid Dysfunction. Arch Med Res. 2005;36(5):608. doi: 10.1016/j.arcmed.2005.03.022.
  12. Colao A., Merola B., Ferone D., et al. Acute and chronic effects of octreotide on thyroid axis in growth hormonesecreting and clinically nonfunctioning pituitary adenomas. Eur J Endocrinol. 1995;133(2):189-94.
  13. Heidegger I., Nagele U., Pircher A., et al. Latent hypothyreosis as a clinical biomarker for therapy response under abiraterone acetate therapy. Anticancer Res. 2014;34(1):307-11.
  14. Trohman R.G., Sharma P.S., McAninch E.A., et al. Amiodarone and the thyroid physiology, pathophysiology, diagnosis and management. Trends Cardiovasc Med. 2019;29(5):285-95. doi: 10.1016/j.tcm.2018.09.005.
  15. Eskes S.A., Wiersinga W.M. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):735-51. Doi: 10.1016/j. beem.2009.07.001.
  16. De Leo S., Braverman L.E. Amiodarone-Induced Thyroid Dysfunction. In: Luster M., Duntas L., Wartofsky L. The Thyroid and Its Diseases. Springer, Cham, 2019. P 417-33.
  17. Udovcic M., Pena R.H., Patham B., et al. Hypothyroidism and the Heart. Methodist Debakey Cardiovasc J. 2017;13(2):55-9. doi: 10.14797/mdcj-13-2-55.
  18. Fukuchi H., Nakashima M., Araki R., et al. Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis. J Clin Pharm Ther. 2009;34(3):329-36. doi: 10.1111/j.1365-2710.2008.00987.x.
  19. Rizzo L.F., Bruno O.D. Amiodarona y disfuncion tiroidea. Med. (B Aires). 2012;72(1):63-74.
  20. Mazokopakis E.E., Karefilakis C.M., Starakis I.K. Escitalopram-induced subclinical hypothyroidism. A case report. Hormon. (Athens). 2012;11(1):101-3. Doi: 10.1007/ BF03401543
  21. Takahashi M., Sawayama E., Sawayama T., Miyaoka H. Reversible paroxetine-induced symptomatic hypothyroidism. Pharmacopsychiat. 2007;40(5):201-2. doi: 10.1055/s-2007-985884.
  22. Mccowen K.C., Garber J.R., Spark R. Elevated serum thyrotropin in thyroxine-treated patients with hypothyroidism given sertraline. N Engl J Med. 1997;337(14):1010-1. Doi: 10.1056/ NEJM199710023371415.
  23. Baruah M.P., Singh R.J. Effects of drugs on thyroid function. Thyroid Res Pract. 2012;9(1):3-6. doi: 10.4103/0973-0354.92387.
  24. Mathiodakis N., Thapa S., Wand G.S., Salvatori T. ACTHsecreting pituitary microadenomas are associated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clin Endocrinol. (Oxf). 2012;77(6):871-76. doi: 10.1111/j.1365-2265.2012.04442.x.
  25. Geenen V. Drug-induced thyroid dysfunction. 2016 Apr 16 [cited 2019 Jul 21]. URL: http:// www.thyroidclub.be/documents/DrugThyroid. pdf.
  26. Cerniglia B., Judson M.A. Infliximab-Induced Hypothyroidism: A Novel Case and Postulations concerning the Mechanism. Case Rep Med. 2013;2013:216939. doi: 10.1155/2013/216939.
  27. Monzani F., Caraccio N., Meucci G., et al. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol. 1999;141(4):325-31.
  28. Durelli L., Ferrero B., Oggero A., et al. Thyroid function and autoimmunity during interferon-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab. 2001;86(8):3525-32. doi: 10.1210/jcem.86.8.7721.
  29. Ramaswamy S., Siddiqui Z., Saharan S., et al. Quetiapine-induced hypothyroidism. J Psychiat Neurosci. 2005;30(1):57.
  30. Liappas J., Paparrigopoulos T., Mourikis I., et al. Hypothyroidism induced by quetiapine: a case report. J Clin Psychopharmacol. 2006;26(2):208-9. doi: 10.1097/01. jcp.0000203227.56494.ff.
  31. Inskip P.D., Veiga L.H.S., Brenner A.V., et al. Hypothyroidism after Radiation Therapy for Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Radiat Res. 2018;190(2):117-32. Doi: 10.1667/ RR14888.1.
  32. Lin C., Guo Z., Mo Z. Nivolumab-induced hypothyroidism: A case report. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019;44(2):222-24. doi: 10.11817/j.issn.1672-734 7.2019.02.0 1 6.
  33. Weijl N.I., Van der Harst D., Brand A., et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol. 1993;11(7):1376-83. Doi: 10.1200/ JCO.1993.11.7.1376.
  34. CAMMS223 Trial Investigators, Coles A.J., Compston D.A., Selmaj K.W., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Eng J Med. 2008;359(17):1786-801. doi: 10.1056/NEJMoa0802670.
  35. Reismuller B., Azizi A.A., Peyrl A., et al. Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatric. Blood Cancer. 2010;54(5):681-86. Doi: 10.1002/ pbc.22409.
  36. Matulonis U.A., Berlin S., Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601-606. Doi: 10.1200/ JCO.2009.23.2777.
  37. De Savary N., Lee R., Vaidya B. Severe hypothyroidism after thalidomide treatment. J R Soc Med. 2004;97(9):443-43. Doi: 10.1258/ jrsm.97.9.443.
  38. Figaro M.K, Clayton Jr.W., Usoh C., et al. Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: results of a retrospective case review. Am J Hematol. 2011;86(6):467-70. Doi: 10.1002/ ajh.22008.
  39. Eyal O, Rose S.R. Autoimmune thyroiditis during leuprolide acetate treatment. J Pediatr. 2004;144(3):394-96.
  40. Щегерцов Д.Ю., Филинюк О.В., Буйнова Л.Н. и др. Нежелательные побочные реакции при лечении больных туберкулезом с множественной лекарственной устойчивостью возбудителя. Туберкулез и болезни легких. 2018;96(3):35-43.
  41. Потанина О.Н. Гипотиреоз у больных туберкулезом, получающих тиоуреидоиминометилпиридиния перхлорат. Медицинский альянс. 2018;1:41-5
  42. Munivenkatappa S., Anil S., Naik B., et al. Druginduced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field. JTR. 2016;4(3):105-10. doi: 10.4236/jtr.2016.43013.
  43. Lai E.C.C., Yang Y.H.K., Lin S.J., et al. Use of antiepileptic drugs and risk of hypothyroidism. Pharmacoepidemiol. Drug Saf. 2013;22(10):1071-79. Doi: 10.1002/ pds.3498.
  44. Оганов Р.Г., Симаненков В.И., Бакулин И.Г и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66.
  45. Миллер О.Н., Старичков С.А., Поздняков Ю.М. и др. Эффективность и безопасность применения пропафенона (Пропанорма®) и амиодарона (Кордарона®) у больных с фибрилляцией предсердий на фоне артериальной гипертонии, ишемической болезни сердца и хронической сердечной недостаточности с сохраненной систолической функцией левого желудочка многоцентровое открытое рандомизированное проспективное сравнительное исследование простор. Российский кардиологический журнал. 2010;(4):55-71
  46. Тарасов А.В., Косых С.А., Бушуева Е.В. и др. Сравнение эффективности инъекционных форм антиаритмических препаратов пропафенона и амиодарона при проведении фармакологической кардиоверсии пароксизмальной фибрилляции предсердий. Consilium Medicum. 2019;21(1):81-6
  47. Kirchhof P, Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1-88. doi: 10.1093/ejcts/ezw313

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##